Research Article

Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer's Disease on CA Isozymes I and II

Volume: 10 Number: 1 June 28, 2017
TR EN

Alzheimer Hastalığı Tedavisinde Kullanılan Rivastigmin ve Galantamin İlaç Etken Maddelerinin CA I ve II İzoenzimleri Üzerine in vitro Etkilerinin İncelenmesi

Abstract

Karbonik anhidraz (CA, EC.4.2.1.1), CO2’in, HCO3- ve H+ iyonlarına iki basamakta dönüşümlü hidratasyonunu katalizleyen, çinko (Zn2+) iyonlu metallo enzimlerden biridir. Fizyolojik ve patolojik birçok proseste önemli rol oynar. Bu çalışmanın amacı, Alzhaimer hastalığının tedavisinde kullanılan bazı ilaç etken maddelerinin insan eritrosit CA I ve II izoenzimleri üzerine in vitro etkilerini araştırmaktır. İnsan kanından CA-I ve II izoenzimleri Sefaroz-4B-L-tirozin-sülfamid afinite kromotografisi yöntemi ile saflaştırıldı. CA I izoenzimi: yaklaşık % 61.7 verimle 122.2 kat; CA II izoenzimi: % 60 verimle 807.5 kat saflaştırılmıştır. CA I için rivastigmin yarışmalı inhibisyon, galantamin ise yarışmasız inhibisyon gösterdi. CA II için ise her iki etken madde de yarışmasız inhibisyon gösterdi. Ki değerleri ise rivastigmin için CA I: 0.79 µM; CA II: 1.08 µM, galantamin için CA I: 0.41µM; CA II: 0.40 µM olarak hesaplandı. Elde edilen sonuçlara bakıldığında en kuvvetli inhibitör galantamin olarak tespit edildi.

Keywords

References

  1. Bartolucci, C., Perola, E., Pilger, C., Fels, G., Lamba, D. 2001. Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: Implications for the design of new anti-Alzheimer drugs. Proteins, 42, 182–191.
  2. Bayram, E., Şentürk, M., Küfrevioğlu, Ö.İ. 2008. Supuran C.S. In vitro inhibition of salicylic acid derivatives on human cytosolic carbonic anhydrase isozymes I and II. Bioorganic and Medicinal Chemistry, 16, 9101-9105.
  3. Beydemir, Ş., Çiftçi, M., Küfrevioğlu, Ö.İ., Büyükokuroğlu, M.E. 2002, Effects of gentamicine sulfate on enzyme activities of carbonic anhydrase from human erythrocytes in vitro and from rat erythrocytes in vivo. Biological and Pharmaceutical Bulletin, 25, 966-969.
  4. Birks, J. 2006. Cholinesterase inhibitors for Alzheimer's disease. The Cochrane Database of Systematic Reviews, 1, CD005593.
  5. Bradford, M.M. 1976. A rapid and sensitive method for the quantitation of micro gram quantities of protein utilizing the principle of protein-dyebinding. Analytical Biochemistry, 72, 248-254.
  6. Cankaya, M., Aktas, M., Kuzucu, M., Gülçin, I., Coban, T.A. 2012 Effects of some drugs on human cord blood erythrocyte carbonic anhydrases I and II: an in vitro study. Journal of Enzyme Inhibition and Medicinal Chemistry, 27(5), 641-645.
  7. Ciftçi, M., Küfrevioglu, O.I., Gündogdu, M., Ozmen, I. 2000. Effects of some antibiotics on enzyme activity of glucose-6-phosphate dehydrogenase from human erythrocytes. Pharmacological Research, 41,109-113.
  8. Coban, T.A., Beydemir, S., Gülcin, I., Gücin, I., Ekinci, D., Innocenti, A. 2009. Sildenafil is a strong activator of mammalian carbonic anhydrase isoforms I-XIV. Bioorganic and Medicinal Chemistry, 17, 5791-5795.

Details

Primary Language

English

Subjects

Engineering

Journal Section

Research Article

Authors

Esra Dilek
Türkiye

Talat Ezmeci This is me

Mukadder Sunar This is me

T. Abdulkadir Çoban This is me

Publication Date

June 28, 2017

Submission Date

October 24, 2016

Acceptance Date

December 22, 2016

Published in Issue

Year 2017 Volume: 10 Number: 1

APA
Dilek, E., Çankaya, M., Ezmeci, T., Sunar, M., & Çoban, T. A. (2017). Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II. Erzincan University Journal of Science and Technology, 10(1), 1-10. https://doi.org/10.18185/erzifbed.320124
AMA
1.Dilek E, Çankaya M, Ezmeci T, Sunar M, Çoban TA. Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II. Erzincan University Journal of Science and Technology. 2017;10(1):1-10. doi:10.18185/erzifbed.320124
Chicago
Dilek, Esra, Murat Çankaya, Talat Ezmeci, Mukadder Sunar, and T. Abdulkadir Çoban. 2017. “Investigation in Vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II”. Erzincan University Journal of Science and Technology 10 (1): 1-10. https://doi.org/10.18185/erzifbed.320124.
EndNote
Dilek E, Çankaya M, Ezmeci T, Sunar M, Çoban TA (June 1, 2017) Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II. Erzincan University Journal of Science and Technology 10 1 1–10.
IEEE
[1]E. Dilek, M. Çankaya, T. Ezmeci, M. Sunar, and T. A. Çoban, “Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II”, Erzincan University Journal of Science and Technology, vol. 10, no. 1, pp. 1–10, June 2017, doi: 10.18185/erzifbed.320124.
ISNAD
Dilek, Esra - Çankaya, Murat - Ezmeci, Talat - Sunar, Mukadder - Çoban, T. Abdulkadir. “Investigation in Vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II”. Erzincan University Journal of Science and Technology 10/1 (June 1, 2017): 1-10. https://doi.org/10.18185/erzifbed.320124.
JAMA
1.Dilek E, Çankaya M, Ezmeci T, Sunar M, Çoban TA. Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II. Erzincan University Journal of Science and Technology. 2017;10:1–10.
MLA
Dilek, Esra, et al. “Investigation in Vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II”. Erzincan University Journal of Science and Technology, vol. 10, no. 1, June 2017, pp. 1-10, doi:10.18185/erzifbed.320124.
Vancouver
1.Esra Dilek, Murat Çankaya, Talat Ezmeci, Mukadder Sunar, T. Abdulkadir Çoban. Investigation in vitro Effects of Rivastigmine and Galantamine Used to Treatment of Alzheimer’s Disease on CA Isozymes I and II. Erzincan University Journal of Science and Technology. 2017 Jun. 1;10(1):1-10. doi:10.18185/erzifbed.320124